The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: A randomized, double-blind clinical trial

被引:48
作者
Chang, DJ
Desjardins, PJ
King, TR
Erb, T
Geba, GP
机构
[1] Merck & Co Inc, West Point, PA USA
[2] Scirex Corp, Austin, TX USA
关键词
D O I
10.1213/01.ANE.0000133141.75831.57
中图分类号
R614 [麻醉学];
学科分类号
100217 [麻醉学];
摘要
Our objective in this study was to compare the analgesic effects of etoricoxib and oxycodone/acetaminophen in a Postoperative dental pain model. Patients experiencing moderate to severe pain after extraction of two or more third molars were randomized to single doses of etoricoxib 120 mg (n = 100), oxycodone/ acetaminophen 10/650 mg (n = 100), or placebo (n = 25). The primary end-point was total pain relief over 6 h. Other end-points included patient global assessment of response to therapy; onset, peak, and duration of effect; and rescue opioid analgesic use. Active treatments were statistically significantly superior to placebo for all efficacy measures. Total pain relief over 6 h for etoricoxib was significantly more than for oxycodone/acetaminophen (P < 0.001). Patient global assessment of response to therapy at 6 and 24 h was superior for etoricoxib. Both drugs achieved rapid onset, although the time was faster for oxycodone/acetaminophen by 5 min.. The peak effect was similar for both drugs. Compared with oxycodone/acetaminophen patients, etoricoxib patients experienced a longer analgesic duration, had a smaller percentage requiring rescue opioids during 6 and 24 h, and required less rescue analgesia during 6 and 24 h. Oxycodone/acetaminophen treatment resulted in more frequent adverse events (AEs), drug-related AEs, nausea, and vomiting compared with etoricoxib treatment. In conclusion, etoricoxib 120 mg provided superior overall efficacy compared with oxycoclone/acetaminophen 10/650 mg and was associated with significantly fewer AEs.
引用
收藏
页码:807 / 815
页数:9
相关论文
共 25 条
[1]
[Anonymous], ADV PAIN RES THERAPY
[2]
BARDEN J, 2003, COCHRANE LIB
[3]
BARDEN J, 2003, BMC ANESTHESIOL, V2, P4
[4]
Oral valdecoxib and injected parecoxib for acute postoperative pain: A quantitative systematic review [J].
Jodie Barden ;
Jayne E Edwards ;
Henry J McQuay ;
R Andrew Moore .
BMC Anesthesiology, 3 (1)
[5]
A multinational randomized, controlled, clinical trial of etoricoxib inthetreatment of rheumatoid arthritis [ISRCTN25142273] [J].
Collantes E. ;
Curtis S.P. ;
Lee K.W. ;
Casas N. ;
McCarthy T. ;
Melian A. ;
Zhao P.L. ;
Rodgers D.B. ;
McCormick C.L. ;
Lee M. ;
Lines C.R. ;
Gertz B.J. .
BMC Family Practice, 3 (1) :1-10
[6]
COOPER S, 1980, ORAL SURG, V6, P496
[7]
Characterization of etoricoxib, a novel, selective COX-2 inhibitor [J].
Dallob, A ;
Hawkey, CJ ;
Greenberg, H ;
Wight, N ;
De Schepper, P ;
Waldman, S ;
Wong, P ;
DeTora, L ;
Gertz, B ;
Agrawal, N ;
Wagner, J ;
Gottesdiener, K .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06) :573-585
[8]
Desjardins P. J., 1996, Clinical Pharmacology and Therapeutics, V59, P130, DOI 10.1038/sj.clpt.1996.21
[9]
Double-masked, single-dose comparison of bromfenac: Sodium, acetaminophen plus oxycodone, and placebo after oral surgery [J].
Fricke, JR ;
Reynolds, D .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1997, 58 (10) :773-783
[10]
Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis [J].
Gottesdiener, K ;
Schnitzer, T ;
Fisher, C ;
Bockow, B ;
Markenson, J ;
Ko, A ;
DeTora, L ;
Curtis, S ;
Geissler, L ;
Gertz, BJ .
RHEUMATOLOGY, 2002, 41 (09) :1052-1061